跳至主要内容
临床试验/NCT00854230
NCT00854230撤回4 期

Pharmacotherapy for HIV Infected Patients With Alcohol Problems

VA Connecticut Healthcare System0 个研究点开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
发起方
主要终点
Frequency of heavy drinking

研究概览

简要总结

This is a randomized double blind clinical trial to test the effect of Naltrexone on HIV infected heavy drinkers. The study will select 40 HIV positive patients who meet criteria for heavy drinking. Treatments include Naltrexone (25-100mg)and placebo. Patients will be treated, followed up, and assessed for a duration of 12 weeks.

The investigators associated hypotheses Hypothesis 1: Naltrexone will reduce the frequency of heavy drinking. Hypothesis 2: Naltrexone will lead to maintenance or improvement in CD4 lymphocyte count and decreased HIV RNA levels.

Hypothesis 3: Naltrexone will lead to a reduction in sexual risk behaviors. Hypothesis 4: Naltrexone will lead to improved adherence to HAART. Hypothesis 5 (Exploratory): Naltrexone will be well-tolerated with minimal side effects and patients will exhibit good treatment retention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Be HIV-positive.
  • •Report heavy drinking 4 or more times in the past 4 weeks. Heavy drinking is defined as 4 or more drinks for women and 5 or more drinks for men on any occasion.
  • •Not be abstinent from alcohol for greater than 30 days.
  • •Be at least 18 years old.
  • •Be able to understand English and provide informed consent

排除标准

  • •Be psychotic or severely psychiatrically disabled.
  • •Have medical conditions that would preclude completing or be of harm during the course of the study.
  • •Have laboratory or clinical evidence of significant liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of the normal range) or cirrhosis.
  • •Have a known contraindication to naltrexone therapy (e.g. taking opioid medication for pain).
  • •Be pregnant, nursing or unable to use an effective method of birth control (women).
  • •Subjects who are taking or use narcotics will not be included because naltrexone will precipitate withdrawal.

研究组 & 干预措施

1

Experimental

Naltrexone

干预措施: Naltrexone (Drug)

2

Placebo Comparator

干预措施: Naltrexone (Drug)

结局指标

主要结局

Frequency of heavy drinking

时间窗: 12 weeks

次要结局

  • HIV biological markers(12 weeks)
  • Sexual risk behavior(12 weeks)
  • Tolerability and retention in alcohol treatment(12 weeks)

研究者

发起方
VA Connecticut Healthcare System
申办方类型
Fed
责任方
Sponsor

相似试验